New Business Development Using Menstrual Blood-Derived Stem Cells and Culture-Derived Products
First written in FY2023-Q2. 9 of 12 entries say "Advanced", first in FY2023. Latest entry: 2026-08-06.
0 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Because the Group has culturing technology for mesenchymal cells, it began in June 2023 to provide contract manufacturing services, based on manufacturing requests from physicians, for culturing mesenchymal cells from stored umbilical cord tissue and manufacturing the secretions from those cells, referred to below as culture supernatant. The number of contracted projects has grown steadily, reaching 37 as of March 2026.」
The contract manufacturing services for family supernatant and related products totaled 37 cases cumulatively by March 2026, specifically demonstrating the increase in contracted services. - 2026-05-13AdvancedEarnings
「In addition, together with iPS Portal Co., Ltd., we are considering the commercialization of manufacturing and storage services for autologous iPS cells derived from umbilical cord blood, while also working to expand the use of umbilical cord-derived conditioned medium in the beauty and private-pay healthcare fields, thereby expanding opportunities to use stored cells.」
The company plans to consider commercializing a service for manufacturing and storing autologous iPS cells derived from umbilical cord blood and to expand the use of umbilical cord-derived conditioned medium in the beauty and private-pay healthcare fields. - FY2026-H1AdvancedAnnual report
「The number of applications for the Family Supernatant Manufacturing Service has grown steadily as the number of umbilical cord storage customers increased further following the introduction of the new HOPECELL plan in November 2024. Given the business's growing importance, the Company made its provider, ミルケア, a consolidated subsidiary from the current interim consolidated accounting period.」
Against the backdrop of an increase in umbilical cord storage customers following the introduction of HOPECELL, applications for the Family Supernatant Manufacturing Service expanded, and the Company made its provider, ミルケア, a consolidated subsidiary. - FY2025AdvancedAnnual report
「Applications for the Family Supernatant Manufacturing Service using umbilical cord-derived products containing growth factors and exosomes have steadily increased, as has the number of family members actually receiving administration.」
The Company explained that the Family Supernatant Manufacturing Service has seen an increase not only in applicants but also in the number of family members actually receiving administration. - FY2025-H1AdvancedAnnual report
「For “umbilical cord,” the launch in June last year of the “Family Conditioned Medium” production service, which produces cultured conditioned medium containing growth factors that promote tissue regeneration and intercellular signaling substances such as exosomes for families who have stored the tissue, raised the umbilical cord storage rate among cord blood customers to more than 50%. Inquiries and applications for the service are also steadily increasing.」
The Company explained that, following the launch of its Family Supernatant Manufacturing Service using umbilical cord culture supernatant, the percentage of umbilical cord storage customers who also stored umbilical cords rose to 50% or more, and inquiries and applications increased. - FY2024-Q3RestatedAnnual report
「In June last year, the Company launched a Family Culture Supernatant Production Service that produces culture supernatant from umbilical cords for customers' families, and is working to further enhance the value of storing umbilical cords.」
The Company continues to offer its service for storage customers using culture supernatant generated through the culturing of umbilical cords as a means of enhancing the value of storage after launch. - FY2024-Q1AdvancedAnnual report
「In June of this year, the Company launched what it described as Japan's first Family Culture Supernatant Manufacturing Service, which cultures umbilical cords to produce and provide culture supernatant for storage customers.」
In June 2023, the Company launched a Family Culture Supernatant Manufacturing Service that produces and provides culture supernatant, a product generated through the culturing of umbilical cords, for storage customers. - FY2023AdvancedAnnual report
「The Company is also actively promoting a new business using products generated during cell culturing, such as exosomes, with a view to launching it in the next fiscal year.」
The Company stated that it is promoting a new business using products generated during the culturing of umbilical cord blood and umbilical cords, with a view to launching it in the next fiscal year. - FY2023-Q3RestatedAnnual report
「Businesses for the Company's storage customers using products generated during the culturing of umbilical cord blood and umbilical cords, such as exosomes,」
The Company is promoting a business for storage customers using products generated during the culturing of umbilical cord blood and umbilical cords, such as exosomes, with a view to launching it in the next fiscal year. - FY2023-Q2First statedAnnual report
「Going forward, the Company plans to develop regenerative medicine using menstrual-blood-derived stem cells as a new cell source, and businesses using products generated during the culturing of umbilical cord blood and umbilical cords,」
The Company presented for the first time in concrete terms, as new business development, the development of regenerative medicine using menstrual-blood-derived stem cells as a new cell source and businesses using products generated during the culturing of umbilical cord blood and umbilical cords.